<DOC>
	<DOCNO>NCT00036257</DOCNO>
	<brief_summary>The purpose study determine maximum tolerate dose evaluate safety efficacy CP-461 patient Chronic Lymphocytic Leukemia .</brief_summary>
	<brief_title>Dose-Escalating Safety Study CP-461 Patients With Chronic Lymphocytic Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<criteria>1 . Relapsed refractory chronic lymphocytic leukemia . 2 . Patients must either intermediate high risk chronic lymphocytic leukemia accord Rai Staging System . 3 . Must fail least 1 prior chemotherapy regimen ( least 1 included fludarabine ) CLL . 4 . No prior therapy within 4 week prior enter study . Patients must fully recover acute effect prior therapy . 5 . Platelet count = 75,000/mm3 , hemoglobin = 8 gm/dL . 6 . Expected remain life span &gt; = three month . 7 . ECOG performance status 0 2 . 8 . 18 year legal age . 9 . Male patient nonpregnant nonlactating female patient , either use adequate birth control , surgically sterile postmenopausal . 10 . Negative serum pregnancy test , fertile female . 11 . Willingness ability sign inform consent document . 1 . Evidence CNS involvement . 2 . Other active malignancy history treatment malignancy ( exclude nonmelanoma skin cancer ) within previous three year . 3 . Previous therapy Campath . 4 . Patients lowrisk chronic lymphocytic leukemia accord Rai Staging System . 5 . Concurrent immunotherapy . 6 . Concurrent use steroid . 7 . Use investigational medication device within 1 month initiate study therapy . 8 . Patients allogeneic bone marrow transplantation . 9 . Total serum bilirubin upper limit normal ; serum creatinine upper limit normal . 10 . AST ALT &gt; 2.5 time upper limit normal . 11 . Any condition medication may interfere conduct study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>Chronic Lymphocytic Leukemia</keyword>
	<keyword>Leukemia</keyword>
	<keyword>CLL</keyword>
</DOC>